This first generic formulations approval in the regulated markets marks is an important milestone in Biocon’s small molecules strategy directed at forward integration from APIs to finished dosages.
Shares of Biocon Ltd are currently trading 1.06% higher at Rs. 462.50 on BSE after the company yesterday announced that it has received European approvals for its Rosuvastatin Calcium 5 mg, 10 mg, 20 mg and 40 mg tablets, a generic equivalent of Crestor tablets, indicated for hyperlipidemia or mixed dyslipidemia.
This first generic formulations approval in the regulated markets marks an important milestone in Biocon’s small molecules strategy of forward integration from APIs to finished dosages.
This first generic formulations approval in the regulated markets marks an important milestone in Biocon’s small molecules strategy of forward integration from APIs to finished dosages.
No comments:
Post a Comment